Hartings AU Phosphorylation Lab: Difference between revisions

From OpenWetWare
Jump to navigationJump to search
No edit summary
No edit summary
 
Line 2: Line 2:
<div style="margin-left: 40px; width: 750px">
<div style="margin-left: 40px; width: 750px">
We are synthesizing novel ruthenium-modified adenosine triphosphate (ATP) analogues. These molecules are being designed so that they can be used by kinases to phosphorylate protein-substrates with a ruthenium-modified phosphate group. Additionally, the ruthenated-phosphate group must be inaccessible to phosphatases such that once the protein-substrate is irreversibly phosphorylated. We plan to use these molecules to study and disrupt intracellular communication with a specific focus on cancerous cells. (The image above shows that one of the ruthenium-modified ATP molecules will look like (left) as well as a rendering of a protein structure with a tyrosine that has been phosphorylated with our modified ATP (right)). You can find more information on this lab at our group [http://hartingslab.com/research/phosphorylation website].<br>
We are synthesizing novel ruthenium-modified adenosine triphosphate (ATP) analogues. These molecules are being designed so that they can be used by kinases to phosphorylate protein-substrates with a ruthenium-modified phosphate group. Additionally, the ruthenated-phosphate group must be inaccessible to phosphatases such that once the protein-substrate is irreversibly phosphorylated. We plan to use these molecules to study and disrupt intracellular communication with a specific focus on cancerous cells. (The image above shows that one of the ruthenium-modified ATP molecules will look like (left) as well as a rendering of a protein structure with a tyrosine that has been phosphorylated with our modified ATP (right)). You can find more information on this lab at our group [http://hartingslab.com/research/phosphorylation website].<br>
<div style="text-align: center;">[[Image:AU BDLabs 1.png|450px]]</div><br>
<div style="text-align: center;">[[Image:Hartings_Kinase_phosphatase_s.png|450px]]</div><br>
</div>
</div>

Latest revision as of 10:35, 27 January 2012



We are synthesizing novel ruthenium-modified adenosine triphosphate (ATP) analogues. These molecules are being designed so that they can be used by kinases to phosphorylate protein-substrates with a ruthenium-modified phosphate group. Additionally, the ruthenated-phosphate group must be inaccessible to phosphatases such that once the protein-substrate is irreversibly phosphorylated. We plan to use these molecules to study and disrupt intracellular communication with a specific focus on cancerous cells. (The image above shows that one of the ruthenium-modified ATP molecules will look like (left) as well as a rendering of a protein structure with a tyrosine that has been phosphorylated with our modified ATP (right)). You can find more information on this lab at our group website.